Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Cerca in Study Connect
  • NCT05335031

Recruiting

A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®) - RPC-1063-MS-003

Aggiornato: 12 aprile, 2022   |   ClinicalTrials.gov

Stampa il riassunto

STAI PRENDENDO IN CONSIDERAZIONE QUESTA SPERIMENTAZIONE?
Stampa questa pagina e la guida alla sperimentazione da utilizzare come supporto nel colloquio con il tuo medico
Utilizza la guida alla sperimentazione per esplorare il processo di partecipazione a una sperimentazione clinica. Cerca di comprendere i fattori chiave da considerare prima di decidere e pensa alle domande da porre al team di professionisti sanitari che sono coinvolti nella conduzione dello studio.
Stampa questa pagina RPC-1063-MS-003
Scarica la guida

SELEZIONI UNA LINGUA

Dettagli della sperimentazione

  • Sesso

  • 18+

    Fascia d'età

  • 1

    Sede/i

  • Recruiting

Opzioni di trattamento

Bracci dello studio
TERAPIA ASSEGNATA
Participants with relapsing-remitting multiple sclerosis (RRMS) treated with Ozanimod

Principali criteri di idoneità

Inclusion Criteria: - Confirmed diagnosis of relapsing-remitting multiple sclerosis (RRMS) - The decision upon treatment with ozanimod must have been made before enrollment and independently of this non-interventional observational study - All data on ozanimod treatment are collected prospectively. The retrospective documentation of ozanimod therapy and enrollment of participants that are already on ozanimod therapy is not allowed Exclusion Criteria: - Special warnings, precautions and contraindications specified in the current version of the Summary of Product Characteristics (SmPC) - Hypersensitivity to the active substance(s) or to any of the excipients of ozanimod as specified in the prescribing information must not be enrolled - Participation in any other clinical studies Other protocol-defined inclusion/exclusion criteria apply

Ti consigliamo vivamente di contattare BMS per segnalare gli effetti collaterali (eventi avversi)
Qui vengono definiti gli effetti collaterali (eventi avversi) e altri eventi da segnalare
Segnala effetti collaterali (eventi avversi) o reclami sulla qualità del prodotto: informazioni mediche

Hai domande? Invia una e-mail

Hai domande?
Invia una e-mail